PHILLIPS-MEDISIZE
Phillips-Medisize , a Molex company, announced expansion of its current Global Innovation and Development (GID) site in Struer, Denmark with a dedicated Manufacturing Development and Clinical build unit, which is scheduled to open in the second quarter of 2020. As a recognized global leader, Phillips-Medisize provides a wide range of custom drug delivery devices, connected health solutions and end-to-end manufacturing services worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005718/en/
The Phillips-Medisize manufacturing facility will be equipped to serve clients with agile set up for cleanroom assembly and molding (e.g. for clinical trials). Approximately 500 m2 of floor space from the existing 8400 m2 building will be repurposed for the cleanroom. The facility is designed to support late stage development of medium- and high-volume products and processes, under GMP and using state-of-the-art equipment.
“This expansion accelerates the manufacture of innovative, compliant and best-in-class products while reducing time to market and lowering launch risk for drug delivery device customers,” said John Horgan, Vice President, Global Sales and Marketing of Phillips-Medisize. “Furthermore, it strengthens our client focus in Scandinavia by complementing the activities of our existing GID in Struer and our newest GID in Copenhagen.”
About Phillips-Medisize:
Phillips-Medisize, LLC, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, and medical device market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005718/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Announces Sustainability Framework, Serving 100 mn Merchants to Advance Inclusive Growth in Re-globalisation16.6.2025 07:00:00 CEST | Press release
- The now-independent company combines techfin and sustainability work in 6T areas: travel, trade, thrive, technology, talent and trust - Company will focus on innovation and collaboration with public & private sectors across 4 business pillars: Unified global wallet gateway, unified merchant payment service, global business account service, and embedded finance service. Ant International, a leading global digital payment, digitisation and financial technology provider, today announced its Sustainability Framework in its first independent Sustainability Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615891282/en/ Ant International announces Sustainability Framework in its Inaugural Sustainability Report A New Chapter of Growth with New Mission and Vision at a Critical Moment 2024 is a transformative year for Ant International, which became independent after a reorganisation of Ant Group. With headquarters in Singa
Andersen Consulting tilføjer Sidat Hyder Morshed til platformen gennem samarbejdsaftale15.6.2025 20:08:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Sidat Hyder Morshed Associates (Sidat Hyder), et managementkonsulent- og teknologiservicefirma, og styrker dermed sin globale kapacitet og tilstedeværelse på et voksende marked. Sidat Hyder blev stiftet i 1986 og tilbyder en lang række ydelser, herunder strategi- og ledelsesrådgivning, HR-rådgivning, rekruttering og outsourcing samt finansiel rådgivning. Firmaet servicerer en mangfoldig portefølje af kunder på tværs af sektorer som finansielle tjenester, energi, produktion, telekommunikation og den offentlige sektor. "Vi har tidligere fungeret som et repræsentativt firma for Arthur Andersen i Pakistan, og vi har en dyb forpligtelse til kvalitet, gennemsigtighed og den bedste service i klassen – værdier, som også er forankret i kulturen hos Andersen Consulting," siger Waqar Hyder, administrerende direktør for Sidat Hyder. "Som samarbejdsfirma er vi nu en del af en platform i verdensklasse, som styrker vores kapacitet, når det kommer til
Cosmetics Industry Icon Leonard A. Lauder, Chairman Emeritus, The Estée Lauder Companies, Passes Away15.6.2025 18:54:00 CEST | Press release
It is with deep sadness that The Estée Lauder Companies Inc. (NYSE: EL) announces that Chairman Emeritus Leonard A. Lauder passed away on June 14, at the age of 92, surrounded by family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615313230/en/ Leonard A. Lauder Mr. Lauder was born in 1933 in New York City, the oldest son of Estée and Joseph H. Lauder, the founders of The Estée Lauder Companies. He was a graduate of the Bronx High School of Science, the University of Pennsylvania’s Wharton School, and the Officer Candidate School of the United States Navy. Mr. Lauder studied at Columbia University’s Graduate School of Business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award. He formally joined Estée Lauder in 1958, and for more than six decades, Mr. Lauder was a visionary and an innovator, helpi
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA202515.6.2025 09:15:00 CEST | Press release
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell productionIn high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic responsewith the majority (82%) realizing a complete responseA reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic responseInitial results demonstrate a favorable safety profile – no dose limiting toxicities were reported, a maximum tolerated dose was not reached and 98% of patients remained on treatmentIncyte will host an in-person analyst and investor event highlighting this data at EHA today, Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 -1:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced the first
Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 15:14:00 CEST | Press release
The Company generated net sales of $46.7 million compared to $34.3 million in the first quarter of 2024Income before income taxes of $7.4 million versus $2.6 million in the first quarter of 2024Backlog of $131.1 million at April 30, 2025, compared to $63.1 million at April 30, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compare
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom